Internal medicine

Percutaneous coronary intervention

Population

Myocardial infarction

Oncology

TIMI

Drug

Food and drug administration

Medicine

Pharmacology

Environmental health

New England Journal of Medicine

In early 2020, the FDA requested that the manufacturer of lorcaserin voluntarily withdraw the drug from the market because of a signal of increased cancer risk. The FDA concluded that the drug's benefits don't outweigh its risks for any identifiable patient population.

Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial